Russ Conroy

Data from the phase 2 RAMP 201 trial may support the potential accelerated approval of avutometinib/defactinib in KRAS-mutated LGSOC.

Findings may support bilateral mastectomy as an alternative for symmetry following unilateral mastectomy for breast cancer.

Investigators aim to identify a clinically useful and safe dose of Illuminare-1 for future studies in surgical cancer care.

Higher response rates with T-DXd occurred in patients with gastric cancer and plasma HER2 amplification in circulating tumor DNA in the DESTINY-Gatric01 trial.

Data from the ALLELE trial support the application for tabelecleucel in patients with EBV-positive post-transplant lymphoproliferative disease.

Data from the INAVO120 trial support the breakthrough therapy designation for inavolisib in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.

Developers voluntarily request withdrawal of accelerated approval status for infigratinib as a treatment for FGFR2-positive cholangiocarcinoma.

The agency issues a complete response letter for the combination due to deficiencies associated with a manufacturing site inspection.

A reduced dosing duration of venetoclax plus hypomethylating agents may be appropriate for elderly patients with acute myeloid leukemia.

Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.

Safety data further support datopotamab deruxtecan as a new treatment option in metastatic hormone receptor–positive, HER2-negative breast cancer.

Data from the TRANSCEND-FL trial support the accelerated approval of lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.

Alternative treatment strategies may be necessary for a high-risk population of patients with acute myeloid leukemia and residual FLT3-ITD.

Data from a phase 1/2 trial support the FDA breakthrough therapy designation for petosemtamab in recurrent head and neck squamous cell carcinoma.

Approval of the self-collection solution may reduce barriers to sample collection and increase access to cervical cancer screening.

Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.

The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.

The progression-free survival end point was not met in the CheckMate -73L trial assessing patients with unresectable stage III non–small cell lung cancer.

Phase 2 data support additional investigation of lifileucel as a treatment for patients with metastatic non–small cell lung cancer.

Treatment with SNB-101 previously demonstrated tolerability among patients with solid tumors in a phase 1 trial.

Phase 2 data support the use of fuzuloparib with or without apatinib in HER2-negative metastatic breast cancer harboring BRCA1/2 germline mutations.

Developers will work with investigators of the phase 3 KEYNOTE-B21 trial to share their findings with the scientific community.

Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.

Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.

Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.

Findings suggest that patients with breast cancer and consistently negative circulating tumor DNA tests tend to have improved clinical outcomes.

Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.

Functional consequences appeared to be lower with HIFU compared with radical prostatectomy in a prospective trial.

Data also highlight a favorable overall survival trend with the acalabrutinib regimen in the phase 3 ECHO trial.

Findings from a health disparities report may support new policies designed to narrow persistent racial and ethnic disparities in health outcomes.